5-HTTLPR

(redirected from 5-hydroxytryptamine)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.
AcronymDefinition
5-HTTLPR5-HydroxyTryptamine (serotonin) Transporter Gene-Linked Polymorphic Region
5-HTTLPRSerotonin-Transporter-Linked Promoter Region (neuroscience)
References in periodicals archive ?
Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients.
Linear regression of the data showed that 6 of the 14 components present in LSW, namely, 5-hydroxytryptamine, bufotalin, cinobufotalin, bufalin, cinobufagin, and resibufogenin, presented good linearity with coefficients of determination ([R.sup.2]) > 0.999.
Shaw, "5-Hydroxytryptamine 1A (5[H.sub.T1A]R) receptors mediate increases in plasma glucose independent of corticosterone," European Journal of Pharmacology, vol.
Lanfumey et al., "Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene," The Journal of Clinical Investigation, vol.
Motomura et al., "CD4+ T cell-mediated immunological control of enterochromaffin cell hyperplasia and 5-hydroxytryptamine production in enteric infection," Gut, vol.
We found that the expression of octopamine receptor was significantly upregulated while 5-hydroxytryptamine receptor 1 was significantly downregulated in neuroactive ligand-receptor interaction pathway in SP AG (Figure S4).
Serotonin (5-hydroxytryptamine; 5-HT) is thought to be critical to the healthy mood regulation and strongly implicated in the vulnerability to anxiety and depression.
Pathological SP behavior can respond to selective serotonin (5-hydroxytryptamine) reuptake inhibitors and to dopamine-blocking psychotropic drugs (3,9).
Information for healthcare professionals: Selective serotonin reuptake inhibitors (SSRIs), selective serotonin-norepinephrine reuptake inhibitors (SNRIs), 5-hydroxytryptamine receptor agonists (triptans), July 19, 2006.
The company stated that SUSTOL is a long-acting formulation of the US FDA-approved 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist granisetron being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC).
The 5-Hydroxytryptamine (5-HT6) receptor messenger RNA (mRNA) occupy high level of receptors in the brain, which mediates the actions of the neurotransmitter 5-hydroxytryptamine (5-HT).